Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 22.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,500 shares of the pharmaceutical company’s stock after purchasing an additional 7,700 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Vertex Pharmaceuticals were worth $21,697,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MADDEN SECURITIES Corp acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $26,000. Meeder Asset Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $26,000. Community Financial Services Group LLC acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $26,000. Elevation Wealth Partners LLC lifted its stake in shares of Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 28 shares in the last quarter. Finally, Pingora Partners LLC purchased a new position in shares of Vertex Pharmaceuticals in the second quarter worth about $32,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Charles Wagner, Jr. sold 15,286 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $547.87, for a total transaction of $8,374,740.82. Following the completion of the sale, the executive vice president owned 31,764 shares in the company, valued at $17,402,542.68. This trade represents a 32.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $547,860.00. Following the sale, the director directly owned 1,109 shares in the company, valued at approximately $607,576.74. The trade was a 47.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 16,557 shares of company stock worth $9,071,071 in the last 90 days. Insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on VRTX. Evercore upped their price objective on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research note on Wednesday, September 2nd. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. Scotiabank boosted their target price on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 3rd. Royal Bank Of Canada upped their price target on Vertex Pharmaceuticals from $576.00 to $600.00 and gave the company an “outperform” rating in a research report on Tuesday, November 3rd. Finally, Daiwa Securities Group increased their price target on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $596.44.

Get Our Latest Report on VRTX

Vertex Pharmaceuticals Trading Down 1.1%

Shares of VRTX stock opened at $514.75 on Friday. The company has a current ratio of 2.34, a quick ratio of 1.89 and a debt-to-equity ratio of 0.17. Vertex Pharmaceuticals Incorporated has a twelve month low of $412.27 and a twelve month high of $568.67. The company’s 50-day moving average price is $522.72 and its 200-day moving average price is $485.26. The stock has a market cap of $130.51 billion, a price-to-earnings ratio of 33.12, a PEG ratio of 2.85 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the previous year, the business posted $4.80 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Featured Stories

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.